Retatrutide, a new dual stimulator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is showing promising outcomes in preliminary patient studies. Ongoing research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/